Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play a more important role?

Gönczi, Lóránt, Végh, Zsuzsanna, Golovics, Petra Anna, Rutka, Mariann, Gecse, Krisztina Barbara, Bor, Renáta, Farkas, Klaudia, Szamosi, Tamás, Bene, László, Gasztonyi, Beáta, Kristóf, Tünde, Lakatos, László, Miheller, Pál, Palatka, Károly, Papp, Mária, Patai, Árpád, Salamon, Ágnes, Tóth, Gábor Tamás, Vincze, Áron, Bíró, Edina, Lovász, Barbara Dorottya, Kürti, Zsuzsanna, Szepes, Zoltán, Molnár, Tamás, Lakatos, Péter László: Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play a more important role?
JOURNAL OF CROHNS & COLITIS, 11 (6). pp. 697-705. ISSN 1873-9946 (2017)

Actions (login required)